|Mr. Gerard J. Michel||CEO & Director||132k||N/A||1963|
|Mr. John Purpura M.S.||Chief Operating Officer||437.37k||N/A||1961|
|Ms. Christine Padula||Interim Principal Accounting Officer||200.3k||N/A||1965|
|Mr. Thomas Johnson||Sr. Director of Corp. Communications||N/A||N/A||N/A|
|Mr. Robin Wagge||Sr. VP of Rubenstein Associates||N/A||N/A||N/A|
|Dr. Johnny John M.D.||Sr. VP Clinical Devel. & Medical Affairs||N/A||N/A||N/A|
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Delcath Systems, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.